<?xml version="1.0" encoding="UTF-8"?>
<!-- generator="FeedCreator 1.8" -->
<?xml-stylesheet href="https://onwar.se/lib/exe/css.php?s=feed" type="text/css"?>
<rdf:RDF
    xmlns="http://purl.org/rss/1.0/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
    xmlns:dc="http://purl.org/dc/elements/1.1/">
    <channel rdf:about="https://onwar.se/feed.php">
        <title>Onwards - flibanserin</title>
        <description></description>
        <link>https://onwar.se/</link>
        <image rdf:resource="https://onwar.se/lib/exe/fetch.php?media=wiki:dokuwiki.svg" />
       <dc:date>2026-10-18T13:13:57+00:00</dc:date>
        <items>
            <rdf:Seq>
                <rdf:li rdf:resource="https://onwar.se/doku.php?id=flibanserin:english_effects_uses_dosage_interactions_warnings&amp;rev=1792034540&amp;do=diff"/>
            </rdf:Seq>
        </items>
    </channel>
    <image rdf:about="https://onwar.se/lib/exe/fetch.php?media=wiki:dokuwiki.svg">
        <title>Onwards</title>
        <link>https://onwar.se/</link>
        <url>https://onwar.se/lib/exe/fetch.php?media=wiki:dokuwiki.svg</url>
    </image>
    <item rdf:about="https://onwar.se/doku.php?id=flibanserin:english_effects_uses_dosage_interactions_warnings&amp;rev=1792034540&amp;do=diff">
        <dc:format>text/html</dc:format>
        <dc:date>2026-10-15T03:22:20+00:00</dc:date>
        <dc:creator>Anonymous (anonymous@undisclosed.example.com)</dc:creator>
        <title>english_effects_uses_dosage_interactions_warnings</title>
        <link>https://onwar.se/doku.php?id=flibanserin:english_effects_uses_dosage_interactions_warnings&amp;rev=1792034540&amp;do=diff</link>
        <description>Onward of the votes, Boehringer Ingelheim had mounted a promotional material effort to kick upstairs the controversial disorderliness of “hypoactive sexual desire”. In 2010, the FDA issued a Perfect Reaction Letter, stating that the fresh drug diligence could non be sanctioned in its electric current configuration. In October 2010, Boehringer proclaimed that it would stop its growth of flibanserin in clean of the FDA&#039;s decision. The rights to the drug were and so transferred to Pullulate Pharmac…</description>
    </item>
</rdf:RDF>
